Reports Q1 revenue $900M, consensus $892.88M. "Strong execution by IDEXX commercial and operational teams drove excellent growth results and financial performance in the first quarter," said CEO Jay Mazelsky. "Commercial engagement and IDEXX innovations are supporting our customers as they work to address growing demand for pet healthcare. IDEXX’s ongoing focus on addressing the needs of veterinary clinics is aligned with developing the long-term global growth opportunity for companion animal diagnostics."
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IDXX:
- IDXX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Idexx Laboratories price target raised to $590 from $543 at Morgan Stanley
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue